NEW HAVEN, Conn.--(BUSINESS WIRE)--Weave Bio, an AI-native life sciences platform company, today announced that its AutoIND solution has received the "BioTech AI Innovation of the Year" award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
Weave's AutoIND streamlines and accelerates the end-to-end preparation process for Investigational New Drug (IND) applications. The software solution offers users intuitive tools for data organization, automatic content generation, editing, review and QC. AutoIND is built on the company's AI-native platform which helps drug developers, medical writers, and regulatory experts build dynamic, living records of therapeutic candidates while removing the manual, repetitive work associated with authoring properly formatted text and tables from study reports to build FDA-ready submission content.
Not only does AutoIND automatically generate draft content based on user uploaded source files, it also allows users to refine the content by instructing the AI themselves, and alerts users to suggested updates when new data is added that conflicts with initial sources. The robust, in-platform support provides a visible record of the content development process while version history and reference tracing ensure data integrity, keeping the users in complete control. AutoIND can ingest and review thousands of pages of study reports in minutes and produce an initial draft IND in a day - improving efficiency and reducing hands on drafting time by up to 70%.
Additional features include in-platform content templates, the ability to customize with your own unique rules, automatic classification of source files, and AI augmentation to refine and review generated content. By extracting and organizing the right data with AI infused throughout the workflow, AutoIND by Weave Bio provides users with groundbreaking efficiency at the critical start of the therapeutic candidate life cycle.
"While conventional IND preparation processes can take more than a year, we have harnessed the power of AI to effortlessly weave together each new piece of data and tell the dynamic story of every IND in the way each therapy deserves," said Ari Caroline, co-founder and CEO of Weave Bio. "Given the complexity of this industry, it is an honor to receive this award from BioTech Breakthrough. The acknowledgement validates the significance of our work and reaffirms our commitment to provide technically robust, AI-enabled solutions that move candidates through regulatory approvals and clinical trials, and out to market faster."
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the world's top companies, solutions and products in the life sciences and biotechnology markets today. This year's program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
"Weave is positioned to be the intelligent drug knowledge management platform of the future. For drug developers, IND applications are essential for getting therapeutic candidates from the lab to humans. However, the submission process is a lengthy, intricate, and a mostly manual process. With hundreds of source files, INDs can take thousands of hours to draft, review and submit," said Bryan Vaughn, Managing Director, BioTech Breakthrough. "By streamlining the IND process, Weave Bio is returning capacity to regulatory teams, lowering costs, and ultimately accelerating the time it takes to get treatments to patients. We're pleased to be able to award them with the 'BioTech AI Innovation of the Year' award!"
About Weave Bio
Weave Bio is an AI-native, life sciences platform company that provides a technically robust, AI-enabled platform for major pain points inherent in the pharma and biotech industries. With its flagship offering, AutoIND, Weave streamlines the Investigational New Drug (IND) application process and enables drug development teams to build a living record of their therapeutic candidates, delivering significant improvements in both efficiency and quality. For more information, please visit weave.bio.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com.
Contacts
Tammy Lyons
314-548-3811
Tammy@weave.bio
